PatrĂ­cia Silva, PhD,  director of science content—

PatrĂ­cia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĂ­cia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by PatrĂ­cia Silva

Two Bayer Inhaled Antibiotics Granted US FDA QIDP Designation

Bayer HealthCare, a global leader in respiratory medicine, recently announced it has received qualified infectious disease product (QIDP) designation from the US Food and Drug Administration for two pipeline inhalation antibiotic drugs: Amikacin inhale and Ciprofloxacin dry powder. The approval of novel inhaled antibiotics are of particular interest to the…

Anthera, Patheon to Co-Manufacture Sollpura for CF Phase 3 Trial

Anthera Pharmaceuticals, Inc., a biopharmaceutical company that specializes in research and development of novel treatments for serious and fatal diseases such as lupus, lupus with nephrotic affectation, and exocrine pancreatic insufficiency (EPI) secondary to cystic fibrosis (CF), has just announced that it has partnered with Patheon®, a contract development and commercial…

N30 Pharma Raises $30 Million to Advance Investigational CF Drug

Clinical-stage biopharmaceutical company, N30 Pharmaceuticals, recently announced that it raised $30 million in a mezzanine round of financing, which will be used to accelerate the development the company’s investigational therapy for the treatment of cystic fibrosis (CF). The novel drug is called N91115 and N30 Pharma has successfully completed its phase…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.